A defined clinical outcome in a high-risk group
A phase III randomized, blinded trial enrolled 386 people with at least two nonmelanoma skin cancers in the preceding five years. Participants received nicotinamide or placebo for twelve months. The rate of new nonmelanoma skin cancers was 23% lower with nicotinamide during treatment, with a 95% confidence interval of 4% to 38%. [1]
The study found no evidence of benefit after treatment stopped and no noteworthy between-group difference in adverse-event number or type during treatment. This was nicotinamide research in a selected high-risk population. It was not a trial of NR, NMN, NAD+ injections or general cosmetic anti-aging. [1]
Why the ingredient name is decisive
Nicotinamide and nicotinamide riboside sound similar, and both may appear in discussions of vitamin B3 and NAD metabolism. Similarity in names is not evidence that a clinical result transfers from one to the other. The intervention in the paper should match the ingredient in the claim.
This distinction matters especially when a citation list is used to imply that an entire product category prevents cancer. The study provides evidence for its own compound, setting and endpoint. It does not certify a mechanism-based extrapolation to another substance.
Our ingredient guide helps separate the better-known NAD-related formats. When checking any additional vitamin B3 compound, apply the same rule: write its full name beside the trial before considering a claimed benefit.
Risk group and duration are part of the finding
The participants’ prior skin-cancer history defined the trial population. A relative reduction in their event rate does not supply an individual prediction for someone with a different baseline risk. Nor does it establish prevention of every type of cancer or a substitute for dermatologic care.
The absence of a demonstrated post-treatment benefit also prevents a claim of permanent protection from a finite course. Keep the follow-up result visible rather than describing only the favorable treatment period.
This is a useful contrast with many early NAD-precursor studies because it measured new clinical events over a year. That stronger endpoint does not authorize broader ingredient or population claims. Evidence can be substantial and still tightly bounded.
If a wellness product cites this trial, ask it to identify the tested compound and explain why the result applies to its own offer. If the answer relies only on a shared metabolic pathway, the missing direct evidence remains missing. The biomarker guide explains another part of that reasoning. Discuss personal skin-cancer prevention with a qualified clinician; this article is about interpreting a specific trial, not selecting a preventive regimen.